Acute lymphoblastic leukemia (ALL) is a fast-growing cancer of the blood and bone marrow involving immature lymphoid cells. It is most common in children but can also occur in adults.
The FDA has approved Tregzi, a donor-derived T-cell immunotherapy, to reduce the risk of chronic graft-versus-host disease following stem cell transplant in adults with high-risk blood cancers. In a pivotal trial, 78% of recipients were alive and free of severe chronic GVHD at one year versus 38.4% with standard transplant.
ASH has published new clinical practice guidelines for frontline and relapsed/refractory ALL management in adolescents and young adults, endorsing pediatric-inspired regimens, asparaginase therapy, and immunotherapy over traditional chemotherapy.
Metabolic pathway scores consistently distinguished patients who developed severe neurologic events after CAR T-cell therapy across six clinical trials, surpassing traditional inflammatory markers in predictive performance.
New market reports forecast significant expansion in CAR T-cell therapy, US pharmaceutical drug delivery, and healthcare nanotechnology sectors, driven by chronic disease prevalence and technological advances.
The FDA approved acalabrutinib combined with venetoclax for chronic lymphocytic leukemia and small lymphocytic leukemia based on phase III trial results. Separately, Yale researchers identified CD25 protein complex as a new drug target for aggressive leukemias.
New research addresses CAR T-cell therapy safety through a venetoclax-controlled on-off switch and a prospective study identifying neurotoxicity risk markers in pediatric patients with acute lymphoblastic leukemia.
West Virginia University Cancer Institute has dosed the first patient in a phase 1/2 trial evaluating subcutaneous blinatumomab for CD19-positive mixed-phenotype acute leukemia, a rare disease with no FDA-approved therapies. The first patient achieved complete remission after one cycle.
ImmunoACT's domestically manufactured CAR-T therapy has treated over 600 patients with relapsed or refractory B-cell malignancies since its 2023 approval, marking India's entry into advanced cellular therapy production.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07516353 |
my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults |
NOT_YET_RECRUITING | NA |
| NCT07252336 |
A Multicenter Study of CAR-T Cells in Primary Ph+All |
RECRUITING | PHASE2 |
| NCT06976736 |
A Long Term Follow-up Study of TScan TCR-T Products |
RECRUITING | |
| NCT06244147 |
Long Term Safety and Efficacy of KSM-66 Ashwagandha in Adults |
COMPLETED | |
| NCT06131801 |
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution |
RECRUITING | |
| NCT06047886 |
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy |
RECRUITING | PHASE1 |
| NCT05940961 |
Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL |
RECRUITING | PHASE2 |
| NCT05592470 |
commd7 Gene Expression in ALL |
UNKNOWN | |
| NCT05550948 |
Use of Transcranial Photobiomodulation to Improve Cognition and Self-Reported Outcomes in Survivors of Childhood Cancer |
ACTIVE_NOT_RECRUITING | NA |
| NCT05476770 |
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies |
RECRUITING | PHASE1 |
